SARS-CoV-2 vaccination in the context of original antigenic sin
- PMID: 34242123
- PMCID: PMC8290366
- DOI: 10.1080/21645515.2021.1949953
SARS-CoV-2 vaccination in the context of original antigenic sin
Abstract
Immunological memory is the ability of the adaptive immune system to ensure a persistent protective effect after immunization. However, it can also be a limitation to building a sufficient level of protective antibodies specific to new mutations of the virus. It is imperative to bear this phenomenon (called "original antigenic sin") in mind and make every effort to overcome its inherent pitfalls when updating current and designing new vaccines.
Keywords: Original antigenic sin; SARS-COV-2; vaccination.
References
-
- JANSSEN BIOTECH, INC . COVID-19 vaccine Ad26.COV2.S VAC31518 (JNJ-78436735). Vaccines and related biological products advisory committee meeting; Meeting date: 2021. February 26. [accessed 2021 March 15]. https://www.fda.gov/media/146219/download.
-
- AstraZeneca . COVID-19 vaccine AstraZeneca. Assessment report. Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000; [accessed 2021 March 15]. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccin....
-
- Francis T, Davenport FM, Hennessy AV.. A serological recapitulation of human infection with different strains of influenza virus. Trans Assoc Am Physicians. 1953;66:231–3. - PubMed
-
- Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009; 58:521–24. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous